ZTS Q3 2025 Earnings
Reported Nov 4, 2025 at 7:06 AM ET · SEC Source
Q3 25 EPS
$1.70
BEAT +4.83%
Est. $1.62
Q3 25 Revenue
$2.40B
MISS 0.23%
Est. $2.41B
vs S&P Since Q3 25
-16.0%
TRAILING MARKET
ZTS -9.6% vs S&P +6.4%
Market Reaction
Did ZTS Beat Earnings? Q3 2025 Results
Zoetis delivered a mixed but broadly solid third quarter, clearing the earnings bar while falling just short on revenue as macro pressures and a strategic portfolio divestiture clouded an otherwise steady performance. Adjusted diluted EPS came in at … Read more Zoetis delivered a mixed but broadly solid third quarter, clearing the earnings bar while falling just short on revenue as macro pressures and a strategic portfolio divestiture clouded an otherwise steady performance. Adjusted diluted EPS came in at $1.70, ahead of the $1.62 consensus estimate by 4.83%, while revenue of $2.40 billion grew just 0.5% year-over-year and edged fractionally below the $2.41 billion analysts had expected. The most material drag on reported results was the divestiture of the medicated feed additive portfolio, which weighed on U.S. Livestock figures even as the segment grew 14% organically; strip that noise away and the underlying business showed genuine momentum, with total organic operational revenue expanding 4%. International operations added a constructive counterbalance, growing 6% organically on broad companion animal and livestock strength. Looking ahead, Zoetis trimmed its full-year revenue guidance to $9.40 billion to $9.48 billion, below prior consensus estimates, while maintaining adjusted diluted EPS guidance of $6.30 to $6.40, a combination that has investors debating whether the company's premium valuation is still justified given a more modest growth outlook.
Key Takeaways
- • Parasiticides portfolio growth including Simparica and Revolution/Stronghold franchises
- • Diagnostics revenue growth
- • Key dermatology product growth including Apoquel Chewable
- • Improved supply of ceftiofur products driving U.S. livestock organic growth of 14%
- • Broad-based international livestock growth across all core species
- • Cost discipline with adjusted cost of sales as a percentage of revenue improving to 28.4% from 29.3%
ZTS YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
ZTS Revenue by Segment
With YoY comparisons, source: SEC Filings
ZTS Revenue by Geography
With YoY comparisons, source: SEC Filings
“We reported 4% organic operational revenue growth and 9% growth in adjusted net income on an organic operational basis, thanks to the relentless focus and consistent execution of our colleagues across the world. While growth moderated in the third quarter in line with our expectations, we achieved significant regulatory milestones, including major new product approvals, geographic expansions and differentiating lifecycle innovations across products and species. With our manufacturing excellence, strong customer relationships and a robust pipeline, we are well positioned to advance animal care, bring new products to market and deliver sustainable growth and value for our shareholders.”
— Kristin Peck, Q3 2025 Earnings Press Release
ZTS Earnings Trends
ZTS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ZTS EPS Trend
Earnings per share: estimate vs actual
ZTS Revenue Trend
Quarterly revenue: estimate vs actual
ZTS Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 BEAT FY | $1.40 | $1.48 | +5.71% | $2.39B | +1.09% |
| FY Full Year | $6.34 | $6.41 | +1.13% | $9.47B | +0.27% |
| Q3 25 BEAT | $1.62 | $1.70 | +4.83% | $2.40B | -0.23% |
| Q2 25 BEAT | $1.61 | $1.76 | +9.15% | $2.46B | +2.18% |
| Q1 25 BEAT | $1.40 | $1.48 | +5.79% | $2.22B | +1.24% |